Literature DB >> 25362255

A role for interleukin-22 in the alleviation of metabolic syndrome.

Elise Dalmas1, Marc Y Donath1.   

Abstract

Increasing evidence points to a role for the immune system in the regulation of metabolism. Two new studies in mice indicate treatment with interleukin-22 restores mucosal immunity in diabetes and alleviates metabolic disease, resulting in improved glycemic control.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25362255     DOI： 10.1038/nm.3748

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  11 in total

Review 1.  Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond.

Authors:  P D Cani; L Geurts; S Matamoros; H Plovier; T Duparc
Journal:  Diabetes Metab       Date:  2014-03-14       Impact factor: 6.041

Review 2.  Targeting inflammation in the treatment of type 2 diabetes: time to start.

Authors:  Marc Y Donath
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

3.  Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes.

Authors:  Xiaoting Wang; Naruhisa Ota; Paolo Manzanillo; Lance Kates; Jose Zavala-Solorio; Celine Eidenschenk; Juan Zhang; Justin Lesch; Wyne P Lee; Jed Ross; Lauri Diehl; Nicholas van Bruggen; Ganesh Kolumam; Wenjun Ouyang
Journal:  Nature       Date:  2014-08-06       Impact factor: 49.962

Review 4.  Functional interactions between the gut microbiota and host metabolism.

Authors:  Valentina Tremaroli; Fredrik Bäckhed
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

5.  Thioredoxin-interacting protein links oxidative stress to inflammasome activation.

Authors:  Rongbin Zhou; Aubry Tardivel; Bernard Thorens; Inpyo Choi; Jürg Tschopp
Journal:  Nat Immunol       Date:  2009-12-20       Impact factor: 25.606

6.  T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes.

Authors:  Elise Dalmas; Nicolas Venteclef; Charles Caer; Christine Poitou; Isabelle Cremer; Judith Aron-Wisnewsky; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srinivas V Kaveri; Karine Clément; Sébastien André; Michèle Guerre-Millo
Journal:  Diabetes       Date:  2014-02-11       Impact factor: 9.461

Review 7.  Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity.

Authors:  Marco Colonna
Journal:  Immunity       Date:  2009-07-17       Impact factor: 31.745

8.  Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals.

Authors:  Elisa Fabbrini; Marina Cella; Steve A McCartney; Anja Fuchs; Nada A Abumrad; Terri A Pietka; Zhouji Chen; Brian N Finck; Dong Ho Han; Faidon Magkos; Caterina Conte; David Bradley; Gemma Fraterrigo; J Christopher Eagon; Bruce W Patterson; Marco Colonna; Samuel Klein
Journal:  Gastroenterology       Date:  2013-04-15       Impact factor: 22.682

Review 9.  Therapeutic opportunities of the IL-22-IL-22R1 system.

Authors:  Robert Sabat; Wenjun Ouyang; Kerstin Wolk
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

10.  Normalization of obesity-associated insulin resistance through immunotherapy.

Authors:  Shawn Winer; Yin Chan; Geoffrey Paltser; Dorothy Truong; Hubert Tsui; Jasmine Bahrami; Ruslan Dorfman; Yongqian Wang; Julian Zielenski; Fabrizio Mastronardi; Yuko Maezawa; Daniel J Drucker; Edgar Engleman; Daniel Winer; H-Michael Dosch
Journal:  Nat Med       Date:  2009-07-26       Impact factor: 53.440
View more
  6 in total

1.  Effect of Different Volumes of Interval Training and Continuous Exercise on Interleukin-22 in Adults with Metabolic Syndrome: A Randomized Trial.

Authors:  Joyce S Ramos; Lance C Dalleck; Rebecca C Stennett; Gregore I Mielke; Shelley E Keating; Lydia Murray; Sumaira Z Hasnain; Robert G Fassett; Michael McGuckin; Ilaria Croci; Jeff S Coombes
Journal:  Diabetes Metab Syndr Obes       Date:  2020-07-09       Impact factor: 3.168

2.  Early-life influences on obesity: from preconception to adolescence.

Authors:  Mark L Wahlqvist; Stephen A Krawetz; Nico S Rizzo; Maria Gloria Dominguez-Bello; Linda M Szymanski; Shari Barkin; Ann Yatkine; Robert A Waterland; Julie A Mennella; Mina Desai; Michael G Ross; Nancy F Krebs; Bridget E Young; Jane Wardle; Christiane D Wrann; John G Kral
Journal:  Ann N Y Acad Sci       Date:  2015-06-02       Impact factor: 5.691

3.  Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences.

Authors:  Ogyi Park; Sung Hwan Ki; Mingjiang Xu; Hua Wang; Dechun Feng; Joseph Tam; Douglas Osei-Hyiaman; George Kunos; Bin Gao
Journal:  Cell Biosci       Date:  2015-05-30       Impact factor: 7.133

4.  Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study.

Authors:  Christian Herder; Julia M Kannenberg; Maren Carstensen-Kirberg; Cornelia Huth; Christa Meisinger; Wolfgang Koenig; Annette Peters; Wolfgang Rathmann; Michael Roden; Barbara Thorand
Journal:  Cardiovasc Diabetol       Date:  2017-01-31       Impact factor: 9.951

5.  Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation.

Authors:  Shaofei Wang; Yubin Li; Jiajun Fan; Xuyao Zhang; Jingyun Luan; Qi Bian; Tao Ding; Yichen Wang; Ziyu Wang; Ping Song; Daxiang Cui; Xiaobin Mei; Dianwen Ju
Journal:  Cell Death Dis       Date:  2017-07-20       Impact factor: 8.469

Review 6.  Therapeutic Opportunities of IL-22 in Non-Alcoholic Fatty Liver Disease: From Molecular Mechanisms to Clinical Applications.

Authors:  Wenjing Zai; Wei Chen; Hongrui Liu; Dianwen Ju
Journal:  Biomedicines       Date:  2021-12-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.